Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | NPC1 | O15118 | 3/20 | 0.30 |
| ▸ | RAB9A | P51151 | 3/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14298063 | 0.89 | ALDH1A1 (0.35) | ACHEALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3366743 | 0.89 | ALDH1A1 (0.39) | ACHEALDH1A1LMNATSHRMEN1 | |
| SCHEMBL3364803 | 0.84 | ALDH1A1 (0.45) | ACHEALDH1A1LMNATSHRMEN1 | |
| SCHEMBL14926297 | 0.82 | ALDH1A1 (0.38) | ALDH1A1LMNATSHRMEN1KMT2A | |
| SCHEMBL4316561 | 0.80 | RELA (0.42) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL8943789 | 0.80 | ACHE (0.45) | ACHEALDH1A1LMNATSHRMAPT | |
| SCHEMBL17618197 | 0.79 | PTGER1 (0.38) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL7486408 | 0.78 | ACHE (0.43) | ACHEALDH1A1LMNATSHRMEN1 | |
| SCHEMBL4893894 | 0.78 | ACHE (0.43) | ACHEALDH1A1LMNATSHRMAPT | |
| SCHEMBL15768410 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNATSHRKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9362506-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-20140291654-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2014-10-02 | — | — | US | disclosed |
| US-8815417-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-20120097929-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120097929-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY2, CRY1, CCNE2 | ACHE 1470/4885ALDH1A1 40/4885LMNA 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.